ICYMI: Phase 2/3 trial results show that Novavax vaccine NVX-CoV2601, based on the Omicron XBB.1.5 variant, outperforms NVX-CoV2373 in neutralizing antibody levels. Findings suggest this could be a more effective booster. #IDsky #MEsky www.contagionlive.com/view/novavax... - ThreadSky | a Reddit-style client for Bluesky

contagionlive.bsky.social • 10 days ago

ICYMI: Phase 2/3 trial results show that Novavax vaccine NVX-CoV2601, based on the Omicron XBB.1.5 variant, outperforms NVX-CoV2373 in neutralizing antibody levels. Findings suggest this could be a more effective booster. #IDsky #MEsky

https://www.contagionlive.com/view/novavax-s-updated-covid-19-vaccine-demonstrates-enhanced-immune-response-in-recent-study

Comments